# Efficacy and Safety of Early Initiation of Vericiguat in Heart Failure After Acute Myocardial Infarction

Study · id `cardio:ct-nct06812546` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06812546](<https://clinicaltrials.gov/study/NCT06812546>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06812546

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 200 participants.

## Technical summary

Registry record NCT06812546. Randomized; single masking; primary purpose treatment. Start 2025-04-01 (anticipated); primary completion 2026-06-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT06812546, source copy `cardio:ctgov-nct06812546-2025-02-06`, retrieved 2026-10-26)
- Planned start: 2025-04-01 (anticipated) (ClinicalTrials.gov record NCT06812546, source copy `cardio:ctgov-nct06812546-2025-02-06`, retrieved 2026-10-26)
- Primary completion: 2026-06-30 (anticipated) (ClinicalTrials.gov record NCT06812546, source copy `cardio:ctgov-nct06812546-2025-02-06`, retrieved 2026-10-26)
- Completion: 2026-12-30 (anticipated) (ClinicalTrials.gov record NCT06812546, source copy `cardio:ctgov-nct06812546-2025-02-06`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT06812546, source copy `cardio:ctgov-nct06812546-2025-02-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06812546-2025-02-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Early Initiation of Vericiguat in Heart Failure After Acute Myocardial Infarction
- Acronym: VIC-MI
- Condition: Heart Failure
- Condition: Acute Myocardial Infarction (AMI)
- Condition: Acute Heart Failure (AHF)
- Intervention (Drug): Vericiguat
- Lead sponsor: Dongying Zhang
- Lead sponsor class: OTHER
- Collaborator: The Second Affiliated Hospital of Chongqing Medical University
- Collaborator class: OTHER
- Collaborator: First Affiliated Hospital of Chongqing Medical University
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as a collaborator: The Second Affiliated Hospital of Chongqing Medical University (`cardio:org-the-second-affiliated-hospital-of-chongqing-medical-739711`)
- Registry lists this organization as a collaborator: First Affiliated Hospital of Chongqing Medical University (`cardio:org-first-affiliated-hospital-of-chongqing-medical-university`)

## Provenance

Content hash: 8f02d5cf8659ceaa3ad444f323ebed4178b7264e10b4e5821975638d00fd5df9
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
